Home Primary Antibodies VEGFB Antibody [E11E24]

research use only

VEGFB Antibody [E11E24]

Catalog No.: F2353

    Application: Reactivity:

    Usage Information

    Dilution
    1:1000
    Application
    WB
    Reactivity
    Rat, Mouse
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    22 kDa 19 kDa
    *Why do the predicted and actual molecular weights differ?
    The following reasons may explain differences between the predicted and actual protein molecular weight.

    Datasheet & SDS

    Biological Description

    Specificity
    VEGFB Antibody [E11E24] detects endogenous levels of total VEGFB protein.
    Clone
    E11E24
    Synonym(s)
    VRF; VEGFB; Vascular endothelial growth factor B; VEGF-B; VEGF-related factor
    Background
    Vascular Endothelial Growth Factor B (VEGFB) is a homodimeric cytokine belonging to the PDGF/VEGF family that promotes angiogenesis and regulates lipid metabolism in metabolically active tissues such as the heart, skeletal muscle, and brown adipose tissue. VEGFB exists as two isoforms, VEGFB167 (heparin-binding, matrix-associated) and VEGFB186 (secreted form), both featuring a conserved cystine-knot motif with six cysteine residues forming three disulfide bonds that stabilize the characteristic VEGF dimer structure essential for receptor binding. VEGFB binds with high affinity to VEGFR-1 (Flt-1) primarily through specific residues in its receptor-binding loops, activating signaling cascades that support endothelial cell survival and proliferation without strong mitogenic activity compared to VEGF-A. VEGFB enhances vascular permeability and stabilization while uniquely regulating fatty acid transport across endothelial barriers via induction of translocase proteins like CD36 and FABP4/5, thereby coordinating blood vessel formation with tissue energy demands. VEGFB signals through VEGFR-1 homodimers or VEGFR-1/VEGFR-2 heterodimers, activating PI3K/Akt and PLCγ pathways to promote vessel maturation rather than sprouting angiogenesis. Dysregulated VEGFB contributes to cardiovascular pathologies, including ischemic heart disease and atherosclerosis, acting as a therapeutic target for improving cardiac vascularization and metabolic homeostasis.
    References
    • https://pubmed.ncbi.nlm.nih.gov/21917115/
    • https://pubmed.ncbi.nlm.nih.gov/16616187/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.